Published in Nat Cell Biol on June 07, 2009
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
Propagation of tau pathology in a model of early Alzheimer's disease. Neuron (2012) 6.23
The spectrum of disease in chronic traumatic encephalopathy. Brain (2012) 5.10
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron (2011) 4.74
The amyloid state of proteins in human diseases. Cell (2012) 4.53
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov (2011) 4.24
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med (2012) 3.98
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci (2009) 3.68
Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem (2011) 3.57
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature (2013) 3.55
α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest (2011) 3.53
Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A (2009) 3.47
Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. PLoS Biol (2014) 3.46
Cell biology. A unifying role for prions in neurodegenerative diseases. Science (2012) 3.34
Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol (2010) 3.34
Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci U S A (2011) 3.23
Prions. Cold Spring Harb Perspect Biol (2011) 3.17
Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron (2013) 3.09
Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron (2012) 3.07
The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res (2012) 3.00
Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol (2011) 2.94
Prion-like spreading of pathological α-synuclein in brain. Brain (2013) 2.92
Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci (2013) 2.90
The many faces of tau. Neuron (2011) 2.89
Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem (2011) 2.86
Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron (2014) 2.83
Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem (2010) 2.67
Biomarker modeling of Alzheimer's disease. Neuron (2013) 2.51
Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem (2012) 2.42
Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med (2012) 2.39
Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci (2015) 2.38
Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Proc Natl Acad Sci U S A (2012) 2.36
Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci (2010) 2.29
Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A (2013) 2.27
Genetic analysis of pathways to Parkinson disease. Neuron (2010) 2.15
Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron (2010) 2.10
Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. J Neurosci (2013) 2.04
The seeds of neurodegeneration: prion-like spreading in ALS. Cell (2011) 2.03
In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci (2011) 2.00
Functional network disruption in the degenerative dementias. Lancet Neurol (2011) 1.98
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci (2010) 1.97
Neuroscience. Garbage truck of the brain. Science (2013) 1.97
Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. J Biol Chem (2010) 1.92
Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain (2013) 1.91
Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem (2011) 1.91
Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol (2013) 1.89
Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A (2013) 1.88
The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med (2010) 1.86
Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med (2014) 1.85
Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature (2015) 1.85
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 1.82
Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol (2010) 1.81
The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol (2010) 1.80
Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem (2012) 1.79
Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep (2012) 1.77
Cell biology: Beyond the prion principle. Nature (2009) 1.70
Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J (2012) 1.70
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med (2011) 1.68
Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol (2010) 1.66
Conformational transformation and selection of synthetic prion strains. J Mol Biol (2011) 1.66
Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol (2012) 1.65
Biology and genetics of prions causing neurodegeneration. Annu Rev Genet (2013) 1.63
Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci (2012) 1.63
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol (2011) 1.62
Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage (2010) 1.62
The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron (2014) 1.59
Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther (2009) 1.57
Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep (2013) 1.57
Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci (2015) 1.53
Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol (2013) 1.51
Transmissible proteins: expanding the prion heresy. Cell (2012) 1.49
Prion-like spread of protein aggregates in neurodegeneration. J Exp Med (2012) 1.49
Neuronal activity regulates extracellular tau in vivo. J Exp Med (2014) 1.48
Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One (2011) 1.45
Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo. Neuron (2016) 1.45
Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol (2013) 1.42
Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res (2012) 1.41
Prion hypothesis: the end of the controversy? Trends Biochem Sci (2010) 1.40
Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A (2011) 1.39
Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. Annu Rev Med (2013) 1.36
A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol (2014) 1.32
Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders. Cell Tissue Res (2012) 1.31
Intercellular (mis)communication in neurodegenerative disease. Neuron (2012) 1.31
PART is part of Alzheimer disease. Acta Neuropathol (2015) 1.31
Motor network degeneration in amyotrophic lateral sclerosis: a structural and functional connectivity study. PLoS One (2010) 1.30
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One (2013) 1.29
Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends Neurosci (2013) 1.29
Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A (2014) 1.28
A deadly spread: cellular mechanisms of α-synuclein transfer. Cell Death Differ (2011) 1.27
Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin Cell Dev Biol (2011) 1.25
Initiation and propagation of neurodegeneration. Nat Med (2010) 1.25
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain (2016) 1.25
Is there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles? Acta Neuropathol (2014) 1.24
Neurodegenerative diseases: expanding the prion concept. Annu Rev Neurosci (2015) 1.24
Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.23
Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One (2009) 1.23
AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PLoS One (2009) 1.23
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Prions. Proc Natl Acad Sci U S A (1998) 27.80
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron (1989) 8.04
Synthetic mammalian prions. Science (2004) 7.35
Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science (2006) 6.47
Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 6.17
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A (1998) 6.13
A century of Alzheimer's disease. Science (2006) 5.84
Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol (1998) 5.42
Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol (1994) 5.20
Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron (1992) 4.22
Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol Acad Sci Hung (1971) 3.71
Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci (2005) 3.69
Epitopes that span the tau molecule are shared with paired helical filaments. Neuron (1988) 3.28
Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett (1995) 3.15
Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci (2007) 3.10
Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci (2002) 2.80
Silver impregnation of Alzheimer's neurofibrillary changes counterstained for basophilic material and lipofuscin pigment. Stain Technol (1988) 2.55
Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci (2008) 2.51
Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. J Neurosci (2000) 2.41
Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc Natl Acad Sci U S A (1991) 2.21
Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci U S A (2002) 2.01
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (2000) 1.92
Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol (2007) 1.77
Inducible proteopathies. Trends Neurosci (2006) 1.67
Abnormal tau-containing filaments in neurodegenerative diseases. J Struct Biol (2000) 1.42
Transmission of mouse senile amyloidosis. Lab Invest (2001) 1.34
Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin generates the AT100 epitope. J Neurochem (2006) 1.21
Affinity purification of human tau proteins and the construction of a sensitive sandwich enzyme-linked immunosorbent assay for human tau detection. J Neurochem (1992) 1.17
Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1. Neurobiol Dis (2004) 1.14
Tauopathy models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 1.06
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell (2010) 7.52
Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science (2006) 6.47
Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J Cell Biol (2002) 5.01
The amyloid state of proteins in human diseases. Cell (2012) 4.53
Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep (2006) 4.06
Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science (2010) 3.98
GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov (2004) 3.93
Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science (2008) 3.59
Tilt-pair analysis of images from a range of different specimens in single-particle electron cryomicroscopy. J Mol Biol (2011) 3.16
Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci (2004) 3.09
JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron (2003) 2.86
Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci (2009) 2.85
In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol (2005) 2.81
Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci (2002) 2.80
Mitofusin-1 protein is a generally expressed mediator of mitochondrial fusion in mammalian cells. J Cell Sci (2003) 2.68
Tau pathology and neurodegeneration. Lancet Neurol (2013) 2.66
Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A (2006) 2.66
Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci (2008) 2.57
Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens (2008) 2.45
gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science (2009) 2.43
Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A (2013) 2.27
Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO J (2007) 2.27
Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A (2009) 2.27
Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci (2003) 2.24
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol (2012) 2.22
Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem (2005) 2.12
Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem (2004) 2.11
The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci (2010) 2.10
Expression pattern of the transcription factor Olig2 in response to brain injuries: implications for neuronal repair. Proc Natl Acad Sci U S A (2005) 2.09
Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem (2002) 2.07
Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J (2003) 2.07
Structure and disassembly of filaments formed by the ESCRT-III subunit Vps24. Structure (2008) 1.95
Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J Neurosci (2005) 1.94
Factors underlying parental decisions about combination childhood vaccinations including MMR: a systematic review. Vaccine (2010) 1.91
Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol (2007) 1.90
p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J (2005) 1.90
Proteasomal degradation of tau protein. J Neurochem (2002) 1.88
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci (2007) 1.85
Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol (2007) 1.77
Reactive glia in the injured brain acquire stem cell properties in response to sonic hedgehog. [corrected]. Cell Stem Cell (2013) 1.77
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem (2004) 1.75
Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci (2002) 1.72
Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry (2006) 1.69
Hippocampal sclerosis dementia: a reappraisal. Acta Neuropathol (2007) 1.68
Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med (2008) 1.68
Age and gender effects on microglia and astrocyte numbers in brains of mice. Brain Res (2002) 1.67
Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A (2003) 1.67
Inducible proteopathies. Trends Neurosci (2006) 1.67
Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci U S A (2005) 1.67
Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer's disease. Biol Psychiatry (2006) 1.66
Soluble Aβ seeds are potent inducers of cerebral β-amyloid deposition. J Neurosci (2011) 1.66
Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett (2004) 1.60
App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci (2003) 1.59
Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro (2010) 1.58
Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2012) 1.58
Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci (2006) 1.57
A structural model for maturation of the hepatitis B virus core. Proc Natl Acad Sci U S A (2005) 1.55
Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain (2012) 1.55
Loss of hypocretin (orexin) neurons with traumatic brain injury. Ann Neurol (2009) 1.54
Shaping mitochondria: The complex posttranslational regulation of the mitochondrial fission protein DRP1. IUBMB Life (2008) 1.52
BRI2 protein regulates β-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE). J Biol Chem (2011) 1.47
Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci (2006) 1.46
Impact of age and caloric restriction on neurogenesis in the dentate gyrus of C57BL/6 mice. Neurobiol Aging (2004) 1.46
Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci U S A (2003) 1.46
MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol (2007) 1.45
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science (2013) 1.45
Global democratic consensus on neuropathological disease criteria. Lancet Neurol (2002) 1.44